Mostrar el registro sencillo del ítem
SUMOylation of p53 mediates interferon activities
dc.contributor.author | Marcos-Villar, Laura | |
dc.contributor.author | Pérez-Girón, José | |
dc.contributor.author | Vilas Martínez, Jessica María | |
dc.contributor.author | Soto Simón, Atenea | |
dc.contributor.author | de la Cruz-Herrera, Carlos | |
dc.contributor.author | Lang, Valerie | |
dc.contributor.author | Collado Rodríguez, Manuel | |
dc.contributor.author | Vidal Figueroa, Anxo | |
dc.contributor.author | Rodríguez, Manuel | |
dc.contributor.author | Muñoz-Fontela, Cesar | |
dc.contributor.author | Rivas ?, Carmen | |
dc.date.accessioned | 2017-06-07T07:11:29Z | |
dc.date.available | 2017-06-07T07:11:29Z | |
dc.date.issued | 2013 | |
dc.identifier.issn | 1538-4101 | |
dc.identifier.uri | http://hdl.handle.net/20.500.11940/3634 | |
dc.description.abstract | There is growing evidence that many host proteins involved in innate and intrinsic immunity are regulated by SUMOylation, and that SUMO contributes to the regulatory process that governs the initiation of the type I interferon (IFN) response. The tumor suppressor p53 is a modulator of the IFN response that plays a role in virus-induced apoptosis and in IFN-induced senescence. Here we demonstrate that IFN treatment increases the levels of SUMOylated p53 and induces cellular senescence through a process that is partially dependent upon SUMOylation of p53. Similarly, we show that vesicular stomatitis virus (VSV) infection induces p53 SUMOylation, and that this modification favors the control of VSV replication. Thus, our study provides evidence that IFN signaling induces p53 SUMOylation, which results in the activation of a cellular senescence program and contributes to the antiviral functions of interferon. | |
dc.language.iso | eng | |
dc.subject.mesh | Antiviral Agents | |
dc.subject.mesh | Interferon-alpha | |
dc.title | SUMOylation of p53 mediates interferon activities | |
dc.type | Artigo | es |
dc.authorsophos | Marcos-Villar, L. | |
dc.authorsophos | Pérez-Girón, J. V. | |
dc.authorsophos | Vilas, J. M. | |
dc.authorsophos | Soto, A. | |
dc.authorsophos | De La Cruz-Herrera, C. F. | |
dc.authorsophos | Lang, V. | |
dc.authorsophos | Collado, M. | |
dc.authorsophos | Vidal, A. | |
dc.authorsophos | Rodríguez, M. S. | |
dc.authorsophos | Muñoz-Fontela, C. | |
dc.authorsophos | Rivas, C. | |
dc.identifier.doi | 10.4161/cc.25868 | |
dc.identifier.isi | 327436300019 | |
dc.identifier.pmid | 23966171 | |
dc.identifier.sophos | 13434 | |
dc.issue.number | 17 | |
dc.journal.title | CELL CYCLE | |
dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago::IDIS.- Instituto de investigaciones sanitarias de Santiago | |
dc.page.initial | 2809 | |
dc.page.final | 2816 | |
dc.rights.accessRights | openAccess | |
dc.subject.decs | Antivirales | |
dc.subject.decs | Interferón-alfa | |
dc.typesophos | Artículo Original | |
dc.volume.number | 12 |